The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Open accessAbstract
BACKGROUND: Reproductive-age women need effective interventions to prevent the acquisition of human immunodeficiency virus type 1 (HIV-1) infection. METHODS: We conducted a randomized, placebo-controlled trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure prophylaxis against HIV-1 infection in women in South Africa, Uganda, and Zimbabwe. HIV-1 testing was performed monthly, and plasma TFV levels were assessed quarterly. RESULTS: Of 12,320 women who were screened, 5029 were enrolled in the study. The rate of retention in the study was 91% during 5509 person-years of follow-up. A total of 312 HIV-1 infections occurred; the incidence of HIV-1 infection was 5.7 per 100 person-years. In the modified intention-to-treat analysis, the effectiveness was -49.0% with TDF (hazard ratio for infection, 1.49; 95% confidence interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and 14.5% with TFV gel (hazard ratio, 0.85; 95% CI, 0.61 to 1.21). In a random sample, TFV was detected in 30%, 29%, and 25% of available plasma samples from participants randomly assigned to receive TDF, TDF-FTC, and TFV gel, respectively. Independent predictors of TFV detection included being married, being older than 25 years of age, and being multiparous. Detection of TFV in plasma was negatively associated with characteristics predictive of HIV-1 acquisition. Elevations of serum creatinine levels were seen more frequently among participants randomly assigned to receive oral TDF-FTC than among those assigned to receive oral placebo (1.3% vs. 0.2%, P=0.004). We observed no significant differences in the frequencies of other adverse events. CONCLUSIONS: None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis. Adherence to study drugs was low. (Funded by the National Institutes of Health; VOICE ClinicalTrials.gov number, NCT00705679.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Adherence can be low (48), and prevention of HIV infection, especially among women, has not been demonstrated (47,49).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citationAntiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Preexposure Prophylaxis for HIV Infection among African Women
Damme, L. V., Corneli, A. L., Ahmed, K., Agot, K. E., Lombaard, J. J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R. N., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,633
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463
A Case-Cohort Design for Epidemiologic Cohort Studies and Disease Prevention Trials
Prentice, R. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.1 · Cited by 1,444
Tanser, F. C., Bärnighausen, T., Grapsa, E., Zaidi, J., & Newell, M. (2013) · Science · doi:10.1126/science.1228160 · Cited by 797
Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation
Liu, T. F., & Shafer, R. W. (2006) · Clinical Infectious Diseases · doi:10.1086/503914 · Cited by 661
Complex Surveys: A Guide to Analysis Using R
Lumley, T. (2010) · doi:10.1002/9780470580066 · Cited by 647
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 999
Eakle, R., Jarrett, C., Bourne, A. H., Stadler, J., & Larson, H. J. (2015) · Systematic Reviews · doi:10.1186/s13643-015-0096-1 · Cited by 20
Siedner, M. J., Hettema, A., Hughey, A. B., Oldenburg, C. E., Kohler, S., Bärnighausen, K., McMahon, S. A., Jia, C., Lejeune, C. L., Matse, S., et al. (2018) · AIDS · doi:10.1097/qad.0000000000001859 · Cited by 20
Adeagbo, O., Mthiyane, N., Herbst, C., Mee, P., Neuman, M., Dreyer, J., Chimbindi, N., Smit, T. K., Okesola, N., Johnson, C., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-033435 · Cited by 20
Ho, D., LeGuyader, C. L. M., Srinivasan, S., Roy, D., Vlaskin, V. A., Chavas, T. E. J., López, C. L., Snyder, J. M., Postma, A., Chiefari, J., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.030 · Cited by 20
Schaefer, R., Leite, P. H. A. D. C., Silva, R., Karim, Q. A., Akolo, C., Cáceres, C. F., Dourado, I. C., Green, K., Hettema, A., Hoornenborg, E., et al. (2022) · UCL Discovery (University College London) · doi:10.60692/3q801-n6x68 · Cited by 20
Pintye, J. C., Kinuthia, J., Abuna, F., Anderson, P. L., Dettinger, J. C., Gómez, L., Haberer, J. E., Marwa, M. M., Ngumbau, N. M., Omondi, P., et al. (2023) · AIDS · doi:10.1097/qad.0000000000003617 · Cited by 20
Dubé, K., Mthimkhulu, D., Ngcobo, W., Mindry, D. L., Maphalala, L., Pillay, V., Tran, W., Korolkova, A., Ndung’u, T., & Dong, K. L. (2023) · HIV Research & Clinical Practice · doi:10.1080/25787489.2023.2243046 · Cited by 20
Fu, J., Dai, Z., Wang, H., Si, M., Chen, X., Wu, Y., Xiao, W., Huang, Y., Yu, F., Mi, G., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293297 · Cited by 21
Duby, Z., Hartmann, M., Mahaka, I. C., Munaiwa, O., Nabukeera, J., Vilakazi, N., Mthembu, F., Colvin, C. J., Mensch, B., & van der Straten, A. (2015) · The Journal of Sex Research · doi:10.1080/00224499.2015.1069784 · Cited by 20
Getting to 90-90-90 in paediatric HIV: What is needed?
Davies, M., Pinto, J., & Bras, M. (2015) · Journal of the International AIDS Society · doi:10.7448/ias.18.7.20770 · Cited by 42
Factors Contributing to the Antiviral Effectiveness of Tenofovir
Murphy, R. A., & Valentovic, M. A. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.243139 · Cited by 20
Fu, R., Owens, D. K., & Brandeau, M. L. (2018) · AIDS · doi:10.1097/qad.0000000000001747 · Cited by 20
Notario-Pérez, F., Martín-Illana, A., Cazorla-Luna, R., Ruíz, R., Peña, J., & Veiga, M.-D. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.02.022 · Cited by 20
Pharmaceutical Approaches to HIV Treatment and Prevention
Yavuz, B., Morgan, J. L., Showalter, L., Crakes, K. R., Dandekar, S., Herrera, C., LiWang, P. J., & Kaplan, D. L. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800054 · Cited by 22
Current State of Microbicide Development
Traoré, Y. L., Chen, Y. A., & Ho, E. A. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1212 · Cited by 22
Fernandes, T., Baxi, K., Sawarkar, S. P., Sarmento, B. F. C. C., & das Neves, J. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1728251 · Cited by 20
Cancio-Suárez, M. R., Díaz-Álvarez, J., Ron, R., Martínez‐Sanz, J., Villar, S. S., Moreno, S., & Sánchez‐Conde, M. (2023) · Pathogens · doi:10.3390/pathogens12070924 · Cited by 20
Baxi, S. M., Vittinghoff, E., Bacchetti, P., Huang, Y., Chillag, K. L., Wiegand, R. E., Anderson, P. L., Grant, R., Greenblatt, R. M., Buchbinder, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190118 · Cited by 19
Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel
Ginsberg, G. M., & Chemtob, D. (2020) · BMC Public Health · doi:10.1186/s12889-020-8334-4 · Cited by 19
Hill, L. M., Saidi, F., Freeborn, K., Amico, K. R., Rosenberg, N. E., Maman, S., Phanga, T., Tsidya, M., Chirwa, S., Zimba, C. C., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253280 · Cited by 19
Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B
Mohareb, A. M., Larmarange, J., Kim, A. Y., Coffie, P. A., Kouamé, M. G., Boyd, A. C., Freedberg, K. A., & Hyle, E. P. (2022) · The Lancet HIV · doi:10.1016/s2352-3018(22)00123-0 · Cited by 19
Gotsche, C. I., Steyn, P. S., Narasimhan, M., Rodolph, M., Baggaley, R. C., & Kiarie, J. N. (2022) · BMJ Sexual & Reproductive Health · doi:10.1136/bmjsrh-2021-201356 · Cited by 19
Landovitz, R. J. (2015) · Europe PMC (PubMed Central) · Cited by 17
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women
Anderson, P. L., Reirden, D. H., & Castillo‐Mancilla, J. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001105 · Cited by 20
Adimora, A. A., Cole, S. R., & Eron, J. J. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix313 · Cited by 19
Pre-exposure Prophylaxis for HIV Infection in the Older Patient: What can be Recommended?
Franconi, I., & Guaraldi, G. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0553-3 · Cited by 19
Duwal, S., Dickinson, L., Khoo, S., & von Kleist, M. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006155 · Cited by 19
Pines, H. A., Strathdee, S. A., Hendrix, C. W., Bristow, C., Vera, A., Magis-Rodríguez, C. L., Martinez, G., Semple, S. J., & Patterson, T. (2018) · International Journal of STD & AIDS · doi:10.1177/0956462418793038 · Cited by 19
Bassett, I. V., Govere, S., Millham, L., Frank, S. C., Dladla, N., Thulare, H., & Psaros, C. (2019) · Journal of Community Health · doi:10.1007/s10900-019-00698-7 · Cited by 19
Kendall, E. A., Durovni, B., Martinson, N. A., Cavalacante, S. C., Motlhaoleng, K., Saraceni, V., Lebina, L., Efron, A., Cohn, S. E., Chon, S., et al. (2019) · AIDS · doi:10.1097/qad.0000000000002380 · Cited by 19
Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis
Ibrahim, M. E., Castillo‐Mancilla, J., Yager, J., Brooks, K. M., Bushman, L. R., Saba, L. M., Kiser, J. J., MaWhinney, S., & Anderson, P. L. (2020) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2020.0108 · Cited by 19
Velloza, J., Poovan, N., Ndlovu, N., Khoza, N., Morton, J. F., Omony, J., Mkwanazi, E., Grabow, C., Donnell, D. J., Munthali, R. J., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266665 · Cited by 20
Transparency of participant incentives in HIV research
Brown, B. J., Galea, J. T., Davidson, P. J., & Khoshnood, K. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)30150-3 · Cited by 19
Katz, A. W. K., Mensch, B., Woeber, K., Musara, P., Etima, J., & van der Straten, A. (2019) · BMC Women s Health · doi:10.1186/s12905-019-0713-6 · Cited by 17
Mayer, K. H., & Krakower, D. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ665 · Cited by 19
Jana, S., Ray, P., Roy, S., Kadam, A. V., Gangakhedkar, R., Rewari, B. B., Moses, S., & Becker, M. (2021) · International Journal of STD & AIDS · doi:10.1177/0956462420983992 · Cited by 19
Thuo, N. B., Polay, M., Leddy, A. M., Ngure, K., Chatterhee, P., Gandhi, M., & Amico, K. R. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03255-3 · Cited by 18
Smith, P. J., Daniels, J., Bekker, L., & Medina‐Marino, A. (2023) · BMC Public Health · doi:10.1186/s12889-023-15306-6 · Cited by 18
Promises and potential pitfalls of long-acting injectable pre-exposure prophylaxis
Pike, C., Rousseau, E., & Bekker, L. (2023) · Southern African Journal of HIV Medicine · doi:10.4102/sajhivmed.v24i1.1497 · Cited by 18
Ngure, K., Friedland, B., Szydlo, D. W., Roberts, S. T., Garcia, M., Levy, L., Akello, C. A., Reddy, K., Palanee‐Phillips, T., Macdonald, P., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287525 · Cited by 18
Preferences for oral and injectable PrEP among qualitative sub-study participants in HPTN 084
Tolley, E. E., Bula, A. K., Chitukuta, M., Ndimande-Khoza, M. N., Etima, J., Namey, E., Kemigisha, D., Makhale, L. M., Tsidya, M., Shoen, M., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309811 · Cited by 18
Drivers of Vaginal Drug Delivery System Acceptability from Internet-Based Conjoint Analysis
Primrose, R. J., Zaveri, T. D., Bakke, A. J., Ziegler, G. R., MOSKOWITZ, H. R., & Hayes, J. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150896 · Cited by 18
Viegas, E., Tembe, N., Nilsson, C., Meggi, B., Maueia, C., Augusto, O. J., Stout, R. R., Scarlatti, G., Ferrari, G., Earl, P. L., et al. (2017) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2017.0121 · Cited by 18
Zuend, C. F., Nomellini, J. F., Smit, J., & Horwitz, M. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-21134-1 · Cited by 18
Liu, A., Zhang, J., Anderson, P. L., Wagner, T. M., Pan, Z., Peda, M., Gomez, K., Beamer, M. A., Jacobson, C. E., Strizki, J., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy652 · Cited by 18
Baron, D., Essien, T., Pato, S., Magongo, M., Mbandazayo, N., Scorgie, F., Rees, H., & Delany‐Moretlwe, S. (2018) · Journal of the International AIDS Society · doi:10.1002/jia2.25175 · Cited by 18
Velloza, J., Bacchetti, P., Hendrix, C. W., Murnane, P. M., Hughes, J. P., Li, M., Curlin, M. E., Holtz, T. H., Mannheimer, S., Marzinke, M. A., et al. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002128 · Cited by 18
Mansoor, L. E., Yende‐Zuma, N., Baxter, C., Mngadi, K. T., Dawood, H., Gengiah, T. N., Samsunder, N., Schwartz, J. L., Doncel, G. F., & Karim, Q. A. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25381 · Cited by 18
Modeling HIV Pre-Exposure Prophylaxis
Straubinger, T., Kay, K., & Bies, R. R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01514 · Cited by 18
HIV Infection in Pregnant Women: A 2020 Update
Harris, K., & Yudin, M. H. (2020) · Prenatal Diagnosis · doi:10.1002/pd.5769 · Cited by 20
Liu, G., Mugo, N. R., Brown, E. R., Mgodi, N. M., Chirenje, Z. M., Marrazzo, J. M., Winer, R. L., Mansoor, L. E., Palanee‐Phillips, T., Siva, S. S., et al. (2021) · AIDS · doi:10.1097/qad.0000000000003004 · Cited by 22
Injectable agents for pre-exposure prophylaxis
Myers, J. E., Ellman, T. M., & Westhoff, C. L. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000166 · Cited by 18
Parsons, T. L., & Marzinke, M. A. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.08.016 · Cited by 18
Tyo, K. M., Minooei, F., Curry, K. C., NeCamp, S. M., Graves, D., Fried, J., & Steinbach-Rankins, J. M. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11040160 · Cited by 18
Invited Commentary: Every Good Randomization Deserves Observation
Westreich, D. J., & Edwards, J. K. (2015) · American Journal of Epidemiology · doi:10.1093/aje/kwv200 · Cited by 18
Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel
Archary, D., Seaton, K. E., Passmore, J.-A. S., Werner, L., Deal, A. W., Dunphy, L. J., Arnold, K. B., Yates, N. L., Lauffenburger, D. A., Bergin, P. J., et al. (2016) · Mucosal Immunology · doi:10.1038/mi.2015.145 · Cited by 17
Lelièvre, J. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz036 · Cited by 17
GREGG, E., Linn, C., Nace, E., Gelberg, L., Cowan, B., & Fulcher, J. A. (2020) · Journal of Primary Care & Community Health · doi:10.1177/2150132720908370 · Cited by 17
Rapid-Release Griffithsin Fibers for Dual Prevention of HSV-2 and HIV-1 Infections
Tyo, K. M., Lasnik, A. B., Zhang, L., Jenson, A. B., Fuqua, J. L., Palmer, K. E., & Steinbach-Rankins, J. M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02139-19 · Cited by 17
Crakes, K. R., Herrera, C., Morgan, J. L., Olstad, K. J., Hessell, A. J., Ziprin, P., LiWang, P. J., & Dandekar, S. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25628 · Cited by 17
A Novel Algorithm to Improve PrEP Adherence Monitoring Using Dried Blood Spots
Devanathan, A. S., Dumond, J. B., Anderson, D. J. C., Moody, K., Poliseno, A., Schauer, A. P., Sykes, C., Gay, C. L., Rosen, E. P., Kashuba, A. D. M., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2845 · Cited by 17
Biomarkers and biometric measures of adherence to use of ARV‐based vaginal rings
Stalter, R. M., Moench, T. R., MacQueen, K. M., Tolley, E. E., & Owen, D. H. (2016) · Journal of the International AIDS Society · doi:10.7448/ias.19.1.20746 · Cited by 17
HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052
Palumbo, P. J., Fogel, J. M., Hudelson, S. E., Wilson, E., Hart, S., Hovind, L., Piwowar‐Manning, E., Wallis, C. L., Papathanasopoulos, M. A., Morgado, M. G., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001623 · Cited by 17
the Partners Mobile Adherence to PrEP (PMAP) Team, Muwonge, T. R., Ngure, K., Katabira, E. T., Mugo, N., Kimemia, G. W., Burns, B., Musinguzi, N., Bambia, F., Baeten, J. M., et al. (2018) · AIDS and Behavior · doi:10.1007/s10461-018-2326-8 · Cited by 17
Fischer, K., Nguyen, K., & LiWang, P. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01084-19 · Cited by 17
Coleman, M. E., Hodges, A. L., Henn, S., & Lambert, C. C. (2020) · Journal of the Association of Nurses in AIDS Care · doi:10.1097/jnc.0000000000000182 · Cited by 17
Intimate partner violence and oral HIV pre-exposure prophylaxis adherence among young African women
Giovenco, D., Pettifor, A. E., Powers, K. A., Hightow‐Weidman, L., Pence, B. W., Celum, C., Delany‐Moretlwe, S., Hosek, S., Donnell, D. J., Anderson, P. L., et al. (2022) · AIDS · doi:10.1097/qad.0000000000003216 · Cited by 18
Mbotwa, C. H., Kazaura, M. R., Moen, K., Leshabari, M. T., Metta, E. O., Leyna, G. H., & Mmbaga, E. J. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08245-2 · Cited by 17
Melody, K., McBeth, S., Kline, C. E., Kashuba, A. D. M., Mellors, J. W., & Ambrose, Z. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01937-15 · Cited by 17
Home Screening for Bacterial Vaginosis to Prevent Sexually Transmitted Diseases
Schwebke, J. R., Lee, J. Y., Lensing, S., Philip, S., Wiesenfeld, H. C., Seña, A. C., Trainor, N., Acevado, N., Saylor, L., Rompalo, A. M., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ975 · Cited by 17
Mukhopadhya, I., Murray, G. I., Berry, S., Thomson, J., Frank, B., Gwozdz, G., Makinde, J., Shattock, R. J., Kelly, C. G., Iannelli, F., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv335 · Cited by 17
Stack, C., Oldenburg, C., Mimiaga, M. J., Elsesser, S. A., Krakower, D., Novak, D. S., Egan, J. E., Stall, R., Safren, S. A., & Mayer, K. H. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000816 · Cited by 18
Design Issues in Transgender Studies
Hughes, J. P., Emel, L., Hanscom, B. S., & Zangeneh, S. Z. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001077 · Cited by 22
Using social networks to understand and overcome implementation barriers in the global HIV response
Harling, G., & Tsai, A. (2019) · Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002203 · Cited by 19
Katz, A. W. K., Naidoo, K., Reddy, K., Chitukuta, M., Nabukeera, J., Siva, S. S., Zimba, C. C., & Montgomery, E. (2020) · AIDS and Behavior · doi:10.1007/s10461-020-02799-0 · Cited by 17
Begg, L., Brodsky, R., Friedland, B., Mathur, S., Sailer, J., & Creasy, G. W. (2020) · BMJ Sexual & Reproductive Health · doi:10.1136/bmjsrh-2020-200662 · Cited by 17
Preventing HIV in Women — Still Trying to Find Their VOICE
Saag, M. S. (2015) · New England Journal of Medicine · doi:10.1056/nejme1415750 · Cited by 17
Corneli, A. L., Meagher, K. M., Henderson, G. E., Peay, H. L., & Rennie, S. (2018) · AIDS and Behavior · doi:10.1007/s10461-018-2358-0 · Cited by 16
Interest in HIV pre-exposure prophylaxis (PrEP) among adolescents and their caregivers in Malawi
Kidman, R. C., Nachman, S., & Kohler, H. (2020) · AIDS Care · doi:10.1080/09540121.2020.1742861 · Cited by 16
Zuend, C. F., Noël‐Romas, L., Hoger, S., McCorriser, S., Westmacott, G., Marrazzo, J. M., Hillier, S. L., Dezzutti, C. S., Squires, K., Bunge, K. E., et al. (2020) · AIDS · doi:10.1097/qad.0000000000002751 · Cited by 16
Delabre, R. M., Bernier, A., Sánchez, F., Vilotitch, A., Chanos, S., Cosmaro, M. L., Langanke, H., Mey, C., James, C., Duken, S. B., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246037 · Cited by 16
Pre-exposure prophylaxis use among HIV serodiscordant couples: a qualitative study in Mozambique
Sack, D. E., Schacht, C. D., Paulo, P., Graves, E., Emílio, A. M., Matino, A., Fonseca, C. L., Aboobacar, A., Rompaey, S. V., & Audet, C. M. (2021) · Global Health Action · doi:10.1080/16549716.2021.1940764 · Cited by 17
Stone, J., Bothma, R., Gomez, G. B., Eakle, R., Mukandavire, C., Subedar, H., Fraser, H., Boily, M., Schwartz, S., Coetzee, J., et al. (2023) · Journal of the International AIDS Society · doi:10.1002/jia2.26063 · Cited by 16
Mugwanya, K. K., Palayew, A., Schaafsma, T., Irungu, E. M., Bukusi, E., Mugo, N., Morton, J., Odoyo, J., Ngure, K., Baeten, J. M., et al. (2023) · Journal of the International AIDS Society · doi:10.1002/jia2.26137 · Cited by 16
The microbiome and HIV prevention strategies in women
Karim, S. S. A., Passmore, J.-A. S., & Baxter, C. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000431 · Cited by 17
Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice
Gallay, P. A., Chatterji, U., Kirchhoff, A. M., Gandarilla, A., Pyles, R. B., Baum, M. M., & Moss, J. A. (2018) · The Open Virology Journal · doi:10.2174/1874357901812010001 · Cited by 16
Stellbrink, H., & Hoffmann, C. (2018) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000480 · Cited by 16
on behalf of the Quatro Study Team, Weinrib, R., Browne, E. N., Shapley‐Quinn, M. K., van der Straten, A., Beksinska, M. E., Mgodi, N. M., Musara, P., Mphili, N., Schwartz, J. L., et al. (2019) · AIDS and Behavior · doi:10.1007/s10461-019-02576-8 · Cited by 16
Mboup, A., Béhanzin, L., Guédou, F. A., Giguère, K., Geraldo, N., Zannou, D. M., Kêkê, R. K., Bachabi, M., Gangbo, F. A., Affolabi, D., et al. (2020) · Medicine · doi:10.1097/md.0000000000020063 · Cited by 16
Cressey, T. R., Siriprakaisil, O., Kubiak, R. W., Klinbuayaem, V., Sukrakanchana, P.-O., Quame‐Amaglo, J., Okochi, H., Tawon, Y., Cressey, R., Baeten, J. M., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.06.037 · Cited by 16
Jin, X., Wang, H., Li, H., Chu, Z., Zhang, J., Hu, Q., Lv, W., Huang, X., Chen, Y., Wang, H., et al. (2020) · BMC Public Health · doi:10.1186/s12889-020-08709-2 · Cited by 16
Balán, I. C., Giguere, R., Lentz, C. L., Kutner, B. A., Kajura-Manyindo, C., Byogero, R., Biira, F. A., Makala, Y., Jambaya, J., Khanyile, N., et al. (2020) · AIDS and Behavior · doi:10.1007/s10461-020-03011-z · Cited by 16
Mahomed, S., Garrett, N., Capparelli, E. V., Baxter, C., Yende‐Zuma, N., Gengiah, T. N., Archary, D., Moore, P. L., Samsunder, N., Barouch, D. H., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030283 · Cited by 16
Mensch, B., Brown, E. R., Liu, K., Marrazzo, J. M., Chirenje, Z. M., Gomez, K., Piper, J. M., Patterson, K., & van der Straten, A. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1312-2 · Cited by 16
Guatelli, J., Siliciano, R. F., Kuritzkes, D. R., & Richman, D. D. (2016) · ASM Press eBooks · doi:10.1128/9781555819439.ch34 · Cited by 16
Lu, Y., Goti, V., Chaturvedula, A., Haberer, J. E., Fossler, M. J., Sale, M. E., Bangsberg, D. R., Baeten, J. M., Celum, C., & Hendrix, C. W. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00559-16 · Cited by 15
Justman, J. E., Nair, G., Hendrix, C. W., Piper, J. M., Marzinke, M. A., Dai, J. Y., Pan, Z., Galaska, B., Levy, L., Schwartz, J. L., et al. (2018) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001655 · Cited by 15
John, S. A., Robles, G., Starks, T. J., & Rendina, H. J. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002058 · Cited by 15
Willingness to use PrEP among female university students in Lesotho
Karletsos, D., Greenbaum, C., Kobayashi, E., & McConnell, M. A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230565 · Cited by 15
Relaño-Rodríguez, I., & Muñoz‐Fernández, M. Á. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249403 · Cited by 15
Metadata
- Authors
- Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., Hendrix, C. W., Dai, J. Y., Ganesh, S., Mkhize, B., Taljaard, M., Parikh, U. M., Piper, J., Mâsse, B., Grossman, C., Rooney, J., Schwartz, J. L., Watts, H., Marzinke, M. A., Hillier, S. L., McGowan, I. M., & Chirenje, Z. M.
- Affiliations
- University of California, San Francisco (US)
- Harborview Medical Center (US)
- Family Health International 360 (US)
- University of Zimbabwe (ZW)
- Centre for the AIDS Programme of Research in South Africa (ZA)
- University of Pittsburgh (US)
- Johns Hopkins University (US)
- South African Medical Research Council (ZA)
- National Institutes of Health (US)
- Eastern Virginia Medical School (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-02-05
- Volume
- 372
- Issue
- 6
- Pages
- 509-518
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4341965
- OpenAlex
- W2044369525
- Cited by
- 1,296
- References
- 19
- Citations by year
- 2026: 32 · 2025: 54 · 2024: 59 · 2023: 78 · 2022: 93 · 2021: 143 · 2020: 125 · 2019: 139 · 2018: 122 · 2017: 140 · 2016: 175 · 2015: 131
- FWCI
- 147.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ResearchSpace (University of KwaZulu-Natal) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (U01AI068633, UM1AI068615, UM1AI069422, UM1AI106707, UM1AI069436, P30AI094189, UM1AI069530, UM1AI069463, UM1AI069469)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- tenofovir disoproxil fumarate, tenofovir/emtricitabine, HIV pre-exposure prophylaxis, HIV-1 prevention, women, women of reproductive age, antiretroviral resistance, tenofovir resistance, drug safety, adverse events, creatinine elevation
- MeSH terms
- Emtricitabine, Tenofovir, Adenine, Administration, Intravaginal, Administration, Oral, Adolescent, Adult, Deoxycytidine, Drug Therapy, Combination, Female, HIV Seropositivity, Humans, Middle Aged, Surveys and Questionnaires, HIV-1, HIV Infections, Africa South of the Sahara, Drug Resistance, Viral, Anti-Retroviral Agents, Medication Adherence, Young Adult, Organophosphonates, Pre-Exposure Prophylaxis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
